Mezzion Pharma Co., Ltd. Logo

Mezzion Pharma Co., Ltd.

Develops novel therapeutics for rare diseases, focusing on Fontan circulation.

140410 | KO

Overview

Corporate Details

ISIN(s):
KR7140410002
LEI:
Country:
South Korea
Address:
서울특별시 강남구 삼성로 570 석천빌딩 7층, 서울특별시

Description

Mezzion Pharma Co., Ltd. is an innovation-driven pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for rare diseases. The company's primary efforts are concentrated on addressing the unmet medical needs of individuals with a Fontan circulation, a palliative surgical procedure for single-ventricle heart defects. Its lead drug candidate, udenafil, is being advanced as a potential first-to-market treatment to improve the physiology of the Fontan circulation. Mezzion is conducting late-stage clinical development, including a confirmatory Phase 3 trial (FUEL-2), to evaluate the therapy's efficacy in adolescent patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-06-12 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 31.0 KB
2023-05-31 00:00
최대주주변경을수반하는주식담보제공계약해제ㆍ취소등
Korean 12.2 KB
2023-05-15 00:00
분기보고서 (2023.03)
Korean 736.6 KB
2023-05-04 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.3 KB
2023-05-04 00:00
주식등의대량보유상황보고서(일반)
Korean 83.6 KB
2023-04-19 00:00
주요사항보고서(유상증자결정)
Korean 24.8 KB
2023-03-31 00:00
정기주주총회결과
Korean 26.2 KB
2023-03-27 00:00
[기재정정]감사보고서제출
Korean 28.7 KB
2023-03-23 00:00
사업보고서 (2022.12)
Korean 1.3 MB
2023-03-22 00:00
감사보고서제출
Korean 25.4 KB
2023-03-21 00:00
투자판단관련주요경영사항(폰탄환자치료제 유데나필의 임상3상(추가 임상) 임상시험계획 승인)
Korean 10.3 KB
2023-03-21 00:00
[기재정정]주주총회소집결의
Korean 20.8 KB
2023-03-21 00:00
[기재정정]주주총회소집공고
Korean 148.6 KB
2023-03-16 00:00
주주총회소집공고
Korean 132.7 KB
2023-03-16 00:00
주주총회소집결의
Korean 16.6 KB

Automate Your Workflow. Get a real-time feed of all Mezzion Pharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mezzion Pharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mezzion Pharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.